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Gestational surrogacy in Australia 2004-2011: treatment, pregnancy and birth 2 




Background: Information on gestational surrogacy arrangement and outcomes 2 
is limited in Australia. 3 
Aims: This national population study investigates the epidemiology of 4 
gestational surrogacy arrangement in Australia: treatment procedures, 5 
pregnancy and birth outcomes. 6 
Materials and Methods: A retrospective study was conducted of 169 intended 7 
parents cycles and 388 gestational carrier cycles in Australia in 2004-2011. 8 
Demographics were compared between intended parents and gestational 9 
carrier cycles. Pregnancy and birth outcomes were compared by number of 10 
embryos transferred. 11 
Results: Over half (54%) intended parents cycles were in women aged <35 12 
years compared to 38% of gestational carrier cycles. About 77% of intended 13 
parents cycles were of nulliparous women compared to 29% of gestational 14 
carrier cycles. Of the 360 embryo transfer cycles, 91% had cryopreserved 15 
embryos transferred and 69% were single embryo transfer (SET) cycles. The 16 
rates of clinical pregnancy and live delivery were 26% and 19% respectively. 17 
There were no differences in rates of clinical pregnancy and live delivery 18 
between SET cycles (27% and 19%) and double embryo transfer (DET) cycles 19 
(25% and 19%). Five of 22 deliveries following DET were twin deliveries 20 
compered to none of 48 deliveries following SET. There were 73 liveborn 21 
babies following gestational surrogacy treatment including 9 liveborn twins. Of 22 
3 
 
these, 22% (16) were preterm and 14% (10) were low birthweight. Preterm birth 1 
was 13% for liveborn babies following SET, lower than the 31% or liveborn 2 
babies following DET. 3 
Conclusions: To avoid adverse outcomes for both carriers and babies, SET 4 




For some women, it is too risky or impossible to carry a pregnancy through and 2 
to give birth to a healthy infant.(1) Surrogacy arrangement is one option for 3 
family formation for these women and their partners. A surrogacy arrangement 4 
is where a woman known as a carrier, who has no intention of becoming 5 
pregnant otherwise, agrees to carry a baby for another person or couple known 6 
as intended parents with the intention that the child will be raised by the 7 
intended parents.(2) A surrogacy arrangement can be classified as either 8 
traditional or gestational surrogacy. Traditional surrogacy usually occurs when 9 
the woman who has agreed to carry the pregnancy for the intended parents is 10 
inseminated with the sperm of the intended father, which means that the baby is 11 
the biological child of the gestational carrier.(1) Gestational surrogacy is when an 12 
embryo, fertilized through assisted reproductive technology (ART) procedures 13 
using the oocytes and sperm from the intended parents, donors or a 14 
combination, is transferred to the gestational carrier.(1) This means that the 15 
gestational carrier has no genetic link to the child.   16 
Traditional surrogacy can be performed at home or in any health settings. In 17 
comparison, gestational surrogacy requires ART treatment including both 18 
clinical and laboratory procedures and is performed exclusively in fertility clinics. 19 
In 2011 in the United States, <1% of the 151,923 ART cycles were gestational 20 
carrier cycles.(3) In the same year in Australia and New Zealand, there were 177 21 
surrogacy arrangement cycles (46 intended patients cycles and 131 gestational 22 
carrier cycles), accounting for 0.3% of all ART treatment cycles (66347) (4). 23 
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Due to the rarity of gestational surrogacy, there is no worldwide statistics on 1 
number of gestational carrier cycles and resulting pregnancy and birth 2 
outcomes. Even though gestational surrogacy treatment cycles performed in 3 
Australia were collected in Australian and New Zealand Assisted Reproduction 4 
Database (ANZARD), there is limited information published in Australia on 5 
demographics of the intended parents and gestational carriers, treatment 6 
procedures, and associated pregnancies and birth outcomes. This national 7 
population study investigates the epidemiology of gestational surrogacy 8 
treatment and resulting pregnancy and birth outcomes in Australia during 2004 9 
to 2011.  10 
MATERIALS AND METHODS 11 
Data 12 
A retrospective population study was conducted of all gestational surrogacy 13 
arrangement cycles in Australia from 1 January 2004 to 31 December 2011.  14 
The research dataset of this study was extracted from the ANZARD. The 15 
ANZARD is a census of all initiated ART treatment cycles undertaken in 16 
Australia and New Zealand. Items on ANZARD are collected annually, in a de-17 
identified format, from all fertility centres within Australia and New Zealand. The 18 
ANZARD includes information on both the ART treatment (oocyte pick-up, 19 
fertilization procedure, use of thawed embryos, blastocyst culture, embryo 20 
transfer, donation of gametes or embryos, and surrogacy arrangement) and 21 




Surrogacy cycles in this study were chosen based on a surrogacy flag in 1 
ANZARD. The final analysis included 169 intended parents cycles and 388 2 
gestational carrier cycles during 2004 to 2011 with resulting pregnancy and birth 3 
outcomes between 2004 and 2012.  4 
Definitions 5 
Age of the gestational carrier and age of the female partner of the intended 6 
parents were in completed years at time of treatment. Parity was grouped as 7 
previous pregnancy of greater than 20 weeks (parous) versus no previous 8 
pregnancy (nulliparous). Embryo transfers were defined by the following: 9 
oocytes fertilized by in vitro fertilization (IVF) or intracytoplasmic sperm injection 10 
(ICSI); fresh or cryopreserved; cleavage (day 2-3) or blastocyst (day 5-6) 11 
embryo; and number of embryos transferred (1 or ≥2). 12 
A clinical pregnancy was defined as satisfying one of the following criteria: 13 
evidence by ultrasound of intrauterine sac(s) or fetal heart(s); examination of 14 
products of conception reveal chronic villi; an ectopic pregnancy that had been 15 
diagnosed laparoscopically or by ultrasound. A live delivery is a birth event in 16 
which one or more baby is liveborn of ≥ 20 weeks gestation or of ≥ 400 grams 17 
birthweight.  18 
Statistical analysis 19 
Descriptive statistics were generated for the gestational surrogacy cycles. 20 
Proportion of preterm birth (< 37 weeks of gestation) and low birthweight (< 21 
2500 grams of birthweight) was calculated for liveborn babies following 22 
surrogacy treatment were presented. Adverse pregnancy and birth outcomes 23 
7 
 
were by number of embryos transferred was compared by Chi-square test. Data 1 
were analysed using the Statistical Package for Social Sciences (SPSS), 2 
version 22. 3 
Ethics 4 
This project was approved by the University of New South Wales Human 5 
Research Ethics Advisory Panel (Reference Number: 2011-7-03). Approval for 6 
use of the data was given by the Fertility Society of Australia. 7 
RESULTS 8 
There were a total of 557 surrogacy cycles during 2004-2011. These include 9 
169 intended parents cycles and 388 gestational carrier cycles, with an average 10 
of 2.3 gestational carrier cycles per every intended parents cycle. Of the 557 11 
surrogacy cycles, 56.2% (313) were from New South Wales, 26.0% (145) were 12 
from Australian Capital Territory. The remaining 17.8% (99) cycles were from 13 
Queensland, Victoria, South Australia and Western Australia. The number of 14 
surrogacy cycles increased from 34 in 2004 to 129 in 2011.  15 
The age range of intended parents (females: 20 to 58 years; males: 26 to 70 16 
years) compared to 22 to 45 years for gestational carriers. Over half (53.8%) 17 
intended parents cycles were in women aged less than 35 years, in contrast to 18 
less than 40% of gestational carrier cycles. The main cause of infertility of 19 
intended parents cycles was female only (45.0%), with 9.4% combined male-20 
female, 16.6% unexplained and 29.0% where infertility was not stated. Over 21 
three quarters of intended parents cycles were of nulliparous women compared 22 
to 29.1% of gestational carrier cycles (Table 1). 23 
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Of the 169 intended parents cycles, 12 (7.1%) used donated oocytes. Husband 1 
or partner’s sperm was used in all intended parents cycles.  2 
Of the 388 gestational carrier cycles, 92.8% (360) had at least one embryo 3 
transferred. The mean number of embryos transferred was 1.4 and ranged from 4 
1 to 3. Of embryo transfer cycles, 91.1% used cryopreserved embryos and 5 
8.9% used fresh embryos. Single embryo transfers (SET) counted for 68.9% 6 
embryo transfer cycles (Table 2).  7 
Of the 360 carrier embryo transfer cycles, 26.4% (95) resulted in a clinical 8 
pregnancy and 18.9% (68) resulted in at least one live delivery. Of the 110 9 
double embryo transfer (DET) carrier cycles, 27 (24.5%) resulted in a clinical 10 
pregnancy and 21 (19.1%) in a live delivery. This was not significantly different 11 
from the 27.4% clinical pregnancy rate (p=0.57) and the 19.0% live delivery rate 12 
(p=0.99) of SET carrier cycles (68 clinical pregnancies and 47 live deliveries 13 
from 248 SET carrier cycles). The overall multiple delivery rate following 14 
gestational carrier cycles was 7.1% (5 twin deliveries and 65 singleton 15 
deliveries). There were no multiple births following SET compared to 22.7% for 16 
DET. The proportion of women giving birth by caesarean section in a 17 
gestational surrogacy arrangement was 47.1% (33 of 70 deliveries).  18 
There were 73 liveborn babies following gestational surrogacy treatment 19 
including 9 liveborn twins. Of the 73 liveborn babies, 21.9% (16) were preterm 20 
and 13.7% (10) were low birthweight. Of the 47 liveborn babies following SET, 5 21 
(10.6%) were low birthweight. In comparison, of the 26 liveborn babies following 22 
DET, 5 (19.2%) were low birthweight (p=0.31). Preterm birth was 12.8% for 23 
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liveborn babies following SET and 30.8% or liveborn babies following DET 1 
(p=0.07).  2 
DISCUSSION 3 
Surrogacy Australia estimates that more than 350 children have been brought 4 
back to Australia as a result of overseas gestational surrogacy arrangements in 5 
2011.(5, 6) This is in stark contrast to the eight babies born on average per year 6 
through surrogacy arrangements in Australia between 2004 and 2010. 7 
Australian-based altruistic surrogacy is extremely rare accounting for 0.13% of 8 
all ART treatment cycles between 2004 and 2011 with an estimated utilization 9 
of 9 gestational carrier cycles per million women of reproductive age.  10 
There is no federal legislation regarding gestational surrogacy arrangements in 11 
Australia and no national monitoring of outcomes for the gestational carriers 12 
and the infants born following surrogacy. In Australia, altruistic 13 
(uncompensated) surrogacy (the carrier does not receive any compensation 14 
beyond the reimbursement of medical and other reasonable expenses) is 15 
regulated at a state and territory level in Australia with seven jurisdictions 16 
having legislation.(7-13)  State legislation also sanctions aspects of surrogacy 17 
arrangement such as ethics, eligibility, age limits, acceptance, compensation, 18 
safety, adoption for the recognition of the intended parents as the legal parents, 19 
and disclosure of the identity of the gestational carrier.(14) 20 
This first national study details current surrogacy practice in Australia and the 21 
pregnancy and perinatal outcomes of surrogates. From 2004-2011, 388 22 
altruistic gestational carriers cycles were performed in Australia, resulting in 360 23 
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embryos transfers, 95 clinical pregnancies, 68 live deliveries and 73 liveborn 1 
babies. The rates of clinical pregnancy (95/360, 26.4%) and live delivery 2 
(68/360, 18.9%) are comparable to the rates of autologous thaw cycles in  3 
Australian and New Zealand in 2011 (27.3% and 20.7% respectively).(4) The 4 
caesarean section rate (47.1%) is slightly lower than overall caesarean section 5 
rate in Australian and New Zealand in 2011 (49.5%).(4) Of the 73 liveborn 6 
babies in this study, the rates of preterm birth (21.9%) and low birthweight 7 
(13.7%) were slightly higher than the rates in Australian and New Zealand in 8 
2011 (17.3% and 13.1% respectively). (4) However, there is no mechanism for 9 
national monitoring of the physical and psychosocial health and wellbeing of 10 
gestational carriers, intended parents and their offspring.  11 
It is without doubt that the interests and safety of all parties in the surrogacy 12 
arrangement need to be paramount. In Australia, there is no national regulation 13 
to protect such interests and safety. Each State has its own legislation that 14 
differs considerably regarding eligibility, age limits, compensation, and safety. A 15 
recent study by Everingham et al. shows that State level legislations have many 16 
perceived barriers and stigma to using surrogacy arrangements in Australia.(6) 17 
As a result most couples consider or use compensated surrogacy arrangements 18 
overseas, mainly in the United States, India and Thailand.(6) As suggested by 19 
Everingham and colleagues, there is a need to review State level regulations, 20 
processes and requirements. A national approach to gestational surrogacy that 21 
ensures the interests and safety of all parties in the surrogacy arrangement and 22 
optimizes the perinatal outcomes should be supported. 23 
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There are a number of ethical issues that this study raise in relation to 1 
surrogacy arrangement and ART practice in Australia. Firstly, of the 200 2 
gestational carrier cycles where parity was available, over one third were in 3 
nulliparous women. The literature shows that gestational carriers have potential 4 
risk of adverse maternal outcomes which would subsequently impact future 5 
pregnancies and family formation. (15, 16) Any risk to the gestational carriers and 6 
their potential for future family formation is ethically unacceptable. (16) It is not 7 
clear how these arrangements with nulliparous women were made. However, 8 
only two states in Australia, Victoria and Western Australia require carriers to 9 
have completed their desired family.(9, 11)  Legislation and practice alike should 10 
be harmonized with Victoria and Western Australia to allow surrogacy only in 11 
parous women. (9, 11)  12 
Secondly, this study found that, of gestational carrier cycles, 91.1% used 13 
cryopreserved embryos and 8.9% used fresh embryos. To avoid the potential 14 
risk of infectious disease transmitted to the carrier, it was recommend in 15 
Australia that all gametes to be transferred to a third person, should be 16 
cryopreserved.(17) The 91.1% of gestational carrier cycles using cryopreserved 17 
embryos are likely related with this recommendation. However, for the 18 
remaining 8.9% cycles where fresh embryos were transferred, we are unable to 19 
investigate why fresh embryos were used and how the potential risk of 20 
infectious disease was assessed. An ethical audit is needed to review how fresh 21 
embryos transfers were arranged. 22 
Thirdly, this study found that the proportion of SET in gestational carrier cycles 23 
was 68.9% which is close to the 73.2% of SET cycles in Australia and New 24 
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Zealand in 2011 (4). Interestingly, there is no difference in the clinical pregnancy 1 
rates between SET and DET in this study. However, this study found that of 2 
pregnancies where fetal hearts were detected, 20.8% (5 of 24) pregnancies 3 
following DET were twin pregnancies. This is significantly higher than the twin 4 
rate of 1.8% (1 of 57) for pregnancies following SET. Multiple pregnancies 5 
including twin pregnancies are the most notable complication following ART 6 
treatment, with demonstrated poorer perinatal outcomes, increased risk of 7 
maternal complications and a great socioeconomic burden on the parents and 8 
health care system.(17-21)  9 
On the other hand, multiple pregnancies following ART treatment are 10 
preventable by reducing the number of embryos per transfer. (19, 20) Since 11 
gestational carriers usually do not have subfertility and the pregnancy rate of 12 
DET is the same as SET, this study advocates that transfer of a single embryo 13 
in all gestational carrier cycles to reduce the potential risk of pregnancy related 14 
complication of carriers. It would also improve perinatal outcomes of the babies 15 
and minimise the socioeconomic burden due to multiple pregnancy following 16 
transfers of multiple embryos. (17-21)   17 
Finally, this study found that only five of the 388 gestational carrier cycles were 18 
in carriers aged less than 25 years. This reflects nationally consistent younger 19 
age limit for gestational carriers being 25 years or older, supported by the 20 
current State legislations of New South Wales, Victoria, Queensland, Western 21 
Australia and Tasmania that prevent surrogacy in young women.(7-9, 11, 12) Of 22 
note, 60% of gestational carrier cycles were in women aged 35 years or older 23 
compared to 50% of intended parents cycles. This disproportion might have 24 
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been related to that some clinics in Australia require a pre-existing relationship 1 
of at least three years between intended patients and gestational carriers. (22-25) 2 
It might also be explained by the circumstances that some mothers and older 3 
sisters carrying a pregnancy for their daughters and younger sisters 4 
respectively .(26-29) 5 
In conclusion, this first national study reported a number of ethical issues in 6 
relation to eligibility criteria to gestational carrier and ART practice. It may be 7 
undesirable practices where more than 25% of gestational carrier cycles were in 8 
nulliparous women. In addition, that about 9% of gestational carrier cycles used 9 
fresh embryos without cryopreservation and quarantining raise ethical concerns. 10 
To avoid potential risk of infectious disease and multiple pregnancy for 11 
gestational carriers, this study suggests that transfer of single cryopreserved 12 
embryo should be advocated for in all gestational surrogacy arrangements. 13 
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Table 1: Surrogacy arrangement in Australia 
Characteristics Intended Parents Gestational Carrier 
 Number Per cent Number Per cent 
Age (years)     
< 25 7 4.1 5 1.3 
25-30 21 12.4 36 9.3 
30-34 63 37.3 105 27.1 
35-39 43 25.4 139 35.8 
≥40 35 20.7 103 26.5 
Cause of infertility     
Male only --- --- --- --- 
Female 76 45.0 --- --- 
Combined female/male 16 9.4   
Unexplained 28 16.6 --- --- 
Not stated 49 29.0 --- --- 
Parity      
Nulliparous 130 76.9 113 29.1 
Parous 23 13.6 180 46.4 




Table 2: ART treatment procedures gestational carrier cycles compared with embryos 
transferred 
ART procedures Carrier cycles 
 Number Per cent 
Fresh/Thaw   
Fresh 32 8.9 
Thaw 328 91.1 
Type of fertilization     
IVF 196 54.4 
ICSI 101 28.1 
Missing 63 17.5 
Stage of embryos   
Cleavage 173 48.1 
Blastocyst 187 51.9 
Number of embryos transferred   
1 248 68.9 
≥ 2 112 31.1 
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Table 3: Pregnancy outcomes of gestational carrier cycles by number of embryos transferred 





Embryo transfer cycles 248 110 360* 
Clinical pregnancies 68 27 95 
Deliveries  48 22 70 
   – Singleton deliveries 48 17 65 
   – Twin deliveries 0 5 5 
Live deliveries 47 21 68 
Number of babies 48 27 75 
Number of liveborn babies 47 26 73 
Clinical pregnancy rate 27.4 24.5 26.4 
Live delivery rate 19.0 19.1 18.9 
Multiple delivery rate 0.0 22.7 7.1 
* Include cycles where 3 or more embryos were transferred. 
 
